Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy
about
Topical n -docosanol for management of recurrent herpes labialisAntiviral therapy for genital herpes for prevention of HIV transmissionThe effects of antiviral therapy of genital herpes in HIV-infected individualsSlipping and sliding: frameshift mutations in herpes simplex virus thymidine kinase and drug-resistanceAntiviral drugs for viruses other than human immunodeficiency virusPredicting the emergence of drug-resistant HSV-2: new predictionsNew strategies against drug resistance to herpes simplex virusThe DNA helicase-primase complex as a target for herpes viral infectionHerpes simplex epithelial and stromal keratitis: an epidemiologic updateGanciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applicationsApproved Antiviral Drugs over the Past 50 YearsHerpes simplex virus: an occupational hazard in dentistryAntiviral drug resistance: mechanisms and clinical implicationsTargeting the ATP-dependent formation of herpesvirus ribonucleoprotein particle assembly as an antiviral approachLongitudinal study on oral shedding of herpes simplex virus 1 and varicella-zoster virus in individuals infected with HIVA core extended naphtalene diimide G-quadruplex ligand potently inhibits herpes simplex virus 1 replicationAgents and strategies in development for improved management of herpes simplex virus infection and disease.Silencing herpes simplex virus type 1 capsid protein encoding genes by siRNA: a promising antiviral therapeutic approach.Diagnosis of genital herpes simplex virus infection in the clinical laboratoryClinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial.Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection model.Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children.Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro.Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and managementUse of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theSkin manifestations of athletes competing in the summer olympics: what a sports medicine physician should know.Quantification of viral DNA and liver enzymes in plasma improves early diagnosis and management of herpes simplex virus hepatitisExtended Release of an Anti-Heparan Sulfate Peptide From a Contact Lens Suppresses Corneal Herpes Simplex Virus-1 Infection.Cultured corneas show dendritic spread and restrict herpes simplex virus infection that is not observed with cultured corneal cells.Laser treatment of recurrent herpes labialis: a literature review.Evaluation of antiviral activities of four local Malaysian Phyllanthus species against herpes simplex viruses and possible antiviral target.CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infectionsInactivation of acyclovir-sensitive and -resistant strains of herpes simplex virus type 1 in vitro by photodynamic antimicrobial chemotherapyGenotypic Characterization of Herpes Simplex Virus Type 1 Isolates in Immunocompromised Patients in Rio de Janeiro, BrazilPlatinum(II) and palladium(II) complexes of pyridine-2-carbaldehyde thiosemicarbazone as alternative antiherpes simplex virus agents.Penciclovir cream--improved topical treatment for herpes simplex infections.Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients.Suppression of transcription factor early growth response 1 reduces herpes simplex virus 1-induced corneal disease in micePotential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females
P2860
Q22306022-09BD6B2D-2B0E-40BA-AF96-39A8B8F6C1F3Q24234315-76E19863-99AC-4FC6-B9AA-1F3572195005Q24245937-4D568AC8-9B38-4C13-A903-37660565E9BFQ24634966-8CC78732-D486-4EF2-ACAD-578F9BD44EDCQ24635330-27BE2F12-2313-429E-BCCA-DD0052286398Q24794184-4F7D15D3-AFD3-4ADE-B206-43CE31730049Q26749548-026B29C6-0BD4-4001-9561-66D1107D3E5CQ26849412-54F90C70-54DE-4D86-90F8-AF2D8C16C858Q26853504-3FC7310A-49BD-44D3-92AB-3D3A51852CD3Q27026675-04DA2115-D524-4522-BBD4-6B706E95DD13Q27755387-E9987843-8F6F-4921-8C94-4C5EA6C9BE32Q28259417-1BAD3B09-AD4E-4796-AA03-502DFBDCA4F1Q28282376-EAF58CAE-A032-4ED8-9150-229B2E57A100Q28314990-E4E4A7FE-68BC-4A2A-8EBC-657F151A5636Q28660303-18FE8878-BBD8-49CC-AC10-B16FCA184DC4Q30250926-C9B3DFA6-4E33-41A0-8F87-7F7FF0CBB6B7Q30350341-E683C0FE-FAD5-4640-BE1B-B43AC195997CQ33560548-CD358B62-671B-47F5-B2FD-563DBF1E1AA4Q33655295-B88A201F-89A3-4B6A-94F5-949762C63378Q33797142-81B8AC9E-4F1D-436C-8C95-D6087189B203Q33798406-4691138D-3E56-4DAA-AAE7-478C4DB97B38Q33826417-E4B83809-68E6-48E8-B299-6F32886D1368Q33935329-0B2B3270-DE9E-42AB-82A7-647B89C4D7D0Q34149904-ACC1A6E9-19B1-44C9-A6D8-B43F96D39FF4Q34190321-5DF14EC3-15B7-4EC9-A471-39107667C2CFQ34212799-9DD81F9A-79AA-4332-ACE7-1A32AA258BAFQ34268978-1C9F5ACC-DD48-4DA9-856F-C3978D9CE3E8Q34354018-4B9DB13B-5A33-47CD-AD91-AC7984B41C9DQ34509564-855B0130-F9DD-4786-BC88-727E3F9441F4Q34551257-C8CA7BF5-7EAB-41FA-9EA7-754DA3808A25Q34667436-075C6AD4-47D4-4F49-BC56-9258A796E041Q35063600-E23AC04C-B1DF-44D8-A9A3-1FFD77EC379EQ35270714-27CA775E-95E5-42C7-9D06-5A0BB8729CDCQ35638983-8B157BA6-1ED7-40EA-A083-53B6FA1E545DQ35788664-062584AC-606E-4C21-9FDB-6244229DE6E1Q35809097-A39AB5C5-EF29-4C06-9323-B0E4C3B5B6E5Q35903494-AB077FE1-D9EC-47A6-99EC-F84CDEB3F8AAQ35923346-1D6C7D6A-CCF4-4A71-A56F-1D6A2D411508Q36171987-68F3E4EF-CB87-4834-A9D1-E4E567D8D2E1Q36173112-A8C6707F-F66A-4CAE-910E-279C30AFAF7B
P2860
Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Herpes simplex virus resistanc ...... o decades of antiviral therapy
@ast
Herpes simplex virus resistanc ...... o decades of antiviral therapy
@en
Herpes simplex virus resistanc ...... o decades of antiviral therapy
@nl
type
label
Herpes simplex virus resistanc ...... o decades of antiviral therapy
@ast
Herpes simplex virus resistanc ...... o decades of antiviral therapy
@en
Herpes simplex virus resistanc ...... o decades of antiviral therapy
@nl
prefLabel
Herpes simplex virus resistanc ...... o decades of antiviral therapy
@ast
Herpes simplex virus resistanc ...... o decades of antiviral therapy
@en
Herpes simplex virus resistanc ...... o decades of antiviral therapy
@nl
P2093
P2860
P1476
Herpes simplex virus resistanc ...... o decades of antiviral therapy
@en
P2093
David Sutton
Jeffry J Leary
Myron J Levin
Robert T Sarisky
Teresa H Bacon
P2860
P304
P356
10.1128/CMR.16.1.114-128.2003
P407
P577
2003-01-01T00:00:00Z